We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore Transoral Robotic Surgery (TORS), a minimally invasive technique for head and neck conditions like cancer and sleep apnea. Learn about its procedure, benefits, recovery, and suitability.

Transoral robotic surgery, often abbreviated as TORS, represents a significant advancement in the field of minimally invasive surgery, particularly for conditions affecting the head and neck region. Unlike traditional open surgeries that require external incisions, TORS allows surgeons to access and operate on tissues within the mouth and throat directly through the oral cavity. This innovative approach utilizes a sophisticated robotic system, most notably the Da Vinci system, which was approved by the U.S. Food and Drug Administration (FDA) in 2009 for the removal of both cancerous and non-cancerous tumors in the head and neck. The increasing adoption of TORS is evident, with a 2020 study indicating a rise in its use from 1.8% in 2012 to 15.1% in 2018 across 73 hospitals.
TORS is primarily employed to treat various head and neck cancers. This includes tumors located in the oropharynx, which encompasses critical areas like the base of the tongue, the soft palate, and the tonsils. Beyond cancer treatment, TORS has also emerged as a viable surgical option for obstructive sleep apnea (OSA). In cases of OSA, the procedure aims to improve airflow by widening the space at the back of the throat, often involving the removal of tonsils or reduction of the tongue base size. In specific instances, TORS can be used for thyroid cancer treatment, a procedure known as thyroidectomy, where the thyroid gland is removed.
While TORS offers numerous benefits, it is not suitable for every patient. The decision to proceed with TORS is highly individualized, taking into account the patient's age, overall health, and specific anatomy. Factors such as the size and location of a tumor are critical. TORS may not be feasible for very large or extensively spread tumors. Additionally, if a tumor is situated very close to vital blood vessels or nerves, the risks associated with TORS might outweigh the benefits, leading a surgeon to recommend an alternative treatment approach. A thorough consultation with a medical professional is essential to determine candidacy.
Preparation for TORS involves a comprehensive evaluation by the surgical team. This typically includes detailed medical history, physical examinations, and potentially imaging studies like CT scans or MRIs to precisely map the surgical area. Patients will receive specific instructions regarding medications, diet, and any necessary pre-operative tests. It's crucial to discuss any concerns or questions with your doctor to ensure you are fully prepared for the procedure.
During a TORS procedure, the surgeon operates from a console, controlling a sophisticated robotic system. This system features a high-definition 3D camera that provides a magnified view of the surgical site, along with robotic arms equipped with specialized surgical instruments. These instruments offer enhanced dexterity and precision, allowing the surgeon to perform intricate maneuvers through the mouth. The transoral approach means no external incisions are made, which is a key characteristic of this minimally invasive technique.
The recovery period following TORS can vary among individuals. However, patients can expect some discomfort, particularly throat pain and difficulty swallowing, especially within the first 48 hours post-surgery. Medications are typically prescribed to manage pain effectively during this initial phase. While the exact recovery timeline differs, most individuals require at least six weeks to fully recuperate from the operation. Following post-operative care instructions diligently is vital for optimal healing and a successful outcome. A 2024 study indicated that most patients experience healthy long-term swallowing and speech function after TORS for oropharyngeal cancer, which is encouraging.
TORS has demonstrated promising outcomes in clinical studies. A 2020 review comparing TORS with open surgery for head and neck cancer revealed that TORS was associated with shorter hospital stays and a reduced risk of complications during and after surgery. Furthermore, a 2020 study focusing on early-stage oropharyngeal cancer patients found that those who underwent TORS had a slightly higher 5-year overall survival rate compared to those who had non-robotic surgery. For OSA, a 2020 study indicated that TORS had comparable success and complication rates to other OSA surgeries, with similar effects on oxygen saturation and sleepiness.
While TORS generally offers advantages, it is not without potential risks. A 2017 study involving 122 TORS operations reported that 16% of patients experienced a major complication directly related to the procedure. Factors such as older age and a larger area of tissue removal were identified as increasing the risk of such complications. Common issues can include bleeding, infection, or damage to surrounding structures. Your medical team will discuss these risks in detail and take all necessary precautions to minimize them.
If you are experiencing persistent symptoms related to head and neck conditions, such as unexplained lumps, persistent sore throat, difficulty swallowing, or changes in voice, it is crucial to consult a doctor. If you have been diagnosed with head and neck cancer or obstructive sleep apnea, discuss the potential benefits and risks of TORS with your healthcare provider. Early diagnosis and appropriate treatment are key to achieving the best possible outcomes.

Explore how Virtual Surgical Planning (VSP) uses 3D imaging and simulation to revolutionize complex surgeries, enhancing precision and patient outcomes.
March 25, 2026

Explore Transoral Robotic Surgery (TORS), a minimally invasive technique for head and neck conditions like cancer and sleep apnea. Learn about its procedure, benefits, recovery, and suitability.
March 25, 2026